GSK, Singapore's A*STAR Unite For EBF Drugs For Emerging Markets
This article was originally published in PharmAsia News
GlaxoSmithKline Plc is joining with Singapore's Agency for Science, Technology and Research for a five-year study of reformulated drugs to meet a growing demand in the BRIC nations and other emerging markets.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.